Is it Time to Buy Vivus on the Dip?

From an investing standpoint, Vivus, Inc. (NASDAQ:VVUS) appeared to get ahead of itself again earlier this year, as hype in the obesity market reached a fever pitch. The company saw its stock price rise to over $22 earlier this month, only to see it take a nosedive and fall 20% last week. Despite these short term losses, Vivus does show solid prospects since the introduction of its anti-obesity drug Qsymia.

VIVUS, Inc. (NASDAQ:VVUS)

For 3Q, Vivus reported EPS at a loss of $0.40, compared to the same quarter last year of $0.10. The loss was contributed to increased selling and administrative expenses on drug commercialization. Most notably were the results for Qsymia, which saw prescriptions up 30%, and over 700 physicians employing the drug in only its fifth week on the market.

In mid-September, the company announced it was launching its drug Qsymia and that it would be eligible for home delivery through CVS Caremark Corporation (NYSE:CVS) and Walgreen Company (NYSE:WAG), two of the nation’s top pharmacies. Both trade in line on various metrics, including P/E and profit margins. The recent fallout over the Express Scripts contract is now being felt by all three companies, with each down over 3% during the last month. CVS has taken the least amount of damage, and is actually seeing positive gains thanks to Walgreen’s mishap. Express is down the most over the last three months at 15%, and will likely continue to feel most of the pain going forward. Walgreen is still attracting shareholder interest thanks to its +3% dividend yield.

Other notable biopharma company and top Vivus competitor Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is also making a name for itself in the anti-obesity market. This drug maker was down 5% after its 3Q results, but its obesity drug Belviq is not expected to hit the market until 1Q 2013. The EPS results showed Arena had lost $0.07 per share, compared to $0.16 for the same quarter last year.

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is another widely popular biopharma company that has traded in wide swings this year. The pharma company took a hit when concerns arose over marketing practices of its drug hit the newswire, and coupled with that were limitations of insurance reimbursement for only specific uses of the drug. The ramifications have been that the company tumbled 40% year to date, but it recently begin paying a dividend that yields over 3%, signaling that management is a strong believer in its earnings stability. This biopharma company has seen several funds dump their 1Q stakes during 2Q, including Palo Alto Investors and Adage Capital, both selling off over 40% of their holdings.

Hedge funds made some big bets in pharma during 2Q, with those investing in Questcor and Vivus losing out big. Both anti-obesity companies continue to be speculative plays. While we see Questcor as being less speculative than the other two, given the company’s positive earnings, the long term growth is likely not as robust for its drug as that of Vivus and Arena. Valuation at this point is virtually useless with both anti-obesity companies still running negative earnings and hemorrhaging cash to commercialize their drugs. Thus, we look to the companies’ long-term growth rates for guidance.

Currently, Arena is up a ridiculous amount year to date at 340%, with Vivus up only 10%. Meanwhile the expected five-year growth rate for Vivus blows Arena’s away. Sell-side analysts expect Vivus to grow EPS at a 5-year CAGR of 50%, compared to Arena’s 25%.

The fund interest in Vivus has also dominated that of Arena. The top fund owners in Arena were small firms with moderate stakes, while Vivus saw both Passport Capital and QVT Financial owning over eight million shares each. QVT’s position made up almost 20% of the firm’s 2Q 13F, while Passport’s made up over 7.5%; check out all the funds owning Vivus. As another vote of confidence for Vivus, Passport announced in a 13G filing last month that it had increased its share ownership by 5%, from 8.1 million shares to 8.5 million shares. Now may not be a bad time to “monkey” Passport into Vivus if you haven’t already.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!